[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350760-105":59,"doc-detail-350760-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","enhancing-the-efficacy-of-b7-h3-targeting-antibody-drug-conjugate-ds-7300a-in-tp53-deficient-tumors-by-inducing-ferroptosis","Enhancing the efficacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deficient tumors by inducing ferroptosis","","Immune checkpoint B7-H3 is an emerging immunotherapy target. DS-7300a, an advanced B7-H3-targeting ADC armed with the topoisomerase I inhibitor DXd, shows clinical activity, yet biomarkers predicting response are unclear. Using prostate cancer as a model, functional p53 is required for DS-7300a anti-tumor efficacy; TP53 defects drive resistance by preventing DXd-induced DNA damage sensing. DS-7300a triggers DNA damage and ATM/ATR/CHK signaling that stabilizes p53 and promotes apoptosis and senescence. TP53-deficient cells maintain high proliferation with reduced apoptosis and senescence. Ferroptosis induction via GPX4 inhibition, supported by increased lipid peroxidation and GPX4 upregulation, enhances DS-7300a efficacy in TP53-deficient tumor models, including humanized B7-H3 models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/enhancing-the-efficacy-of-b7-h3-targeting-antibody-drug-conjugate-ds-7300a-in-tp53-deficient-tumors-by-inducing-ferroptosis/350760/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/enhancing-the-efficacy-of-b7-h3-targeting-antibody-drug-conjugate-ds-7300a-in-tp53-deficient-tumors-by-inducing-ferroptosis/350760.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is DS-7300a and what payload does it deliver?","Question",{"text":112,"@type":113},"DS-7300a is a B7-H3-targeting antibody-drug conjugate. It is armed with DXd, a selective topoisomerase I inhibitor payload.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does TP53 status affect the response to DS-7300a?",{"text":117,"@type":113},"Functional p53 is required for DS-7300a efficacy. TP53 defects confer resistance by impairing sensing of DXd-induced DNA damage, leading to low apoptosis and senescence despite DNA damage-related signaling being engaged in p53-proficient cells.",{"name":119,"@type":110,"acceptedAnswer":120},"How was ferroptosis used to overcome DS-7300a resistance?",{"text":121,"@type":113},"DS-7300a treatment increases lipid peroxidation in TP53-deficient cancer cells and upregulates GPX4. Pharmacological inhibition of GPX4 induces ferroptosis and enhances DS-7300a efficacy in TP53-deficient tumor models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350760,1790164004,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Oncogene [www.nature.com/onc](www.nature.com/onc)  \nARTICLE OPEN   \nEnhancing the efﬁcacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deﬁcient tumors by inducing ferroptosis  \nJavier Leo1,2, Feiyu Chen1, Wei Shi1, Xin Liang1, Chenling Meng1, Qianlin Gu1, Yaman Albittar1, Zhen Fan1, Jie Zhang1, Boyi Gan 1  \n,  \nSangeeta Goswami3,4,5, Kendra S. Carmon 2,6, Daniel E. Frigo 2,3,7, Ana Aparicio3 and Di Zhao 1,2 ✉  \n© The Author(s) 2026  \n\n| | Immune checkpoint B7-H3 is an emerging target for immunotherapy. DS-7300a is an advanced B7-H3-targeting antibody-drug conjugate (ADC) warheaded with the topoisomerase I inhibitor DXd. DS-7300a has demonstrated clinical activity, but molecular biomarkers to predict its therapeutic response remain elusive. TP53 is one of the most mutated tumor suppressor genes across cancers, and effective therapies are urgently needed for TP53-deﬁcient cancers. Using prostate cancer (PCa) as a model system, we reported that DS-7300a’s anti-tumor efﬁcacy is highly dependent on functional p53 in cancer cells, and TP53 defects confer resistance to DS-7300a. Mechanistically, we found that DS-7300a and its payload, DXd, induce DNA damage and activate the ATM/ ATR/CHK signaling cascade, thereby stabilizing p53 and inducing a pro-apoptotic and senescence-associated transcriptome. In contrast, TP53-deﬁcient cells fail to sense DXd-induced DNA damage, maintain a high proliferation rate, and exhibit low levels of apoptosis and senescence, thereby conferring resistance to DS-7300a. Ferroptosis is an iron-dependent form of regulated cell death triggered by lipid peroxidation, which is mechanistically and morphologically distinct from apoptosis. Interestingly, DS-7300a treatment elevates lipid peroxidation in TP53-deﬁcient cancer cells and upregulates glutathione peroxidase 4 (GPX4), an antioxidant enzyme that mitigates lipid peroxidation. Using isogeneic xenograft models and a newly developed humanized B7-H3 PCa model, we demonstrated that inducing ferroptosis by pharmacological inhibition of GPX4 enhances DS-7300a’s efﬁcacy in TP53-deﬁcient tumors. Our studies demonstrate that TP53 status dictates anti-tumor responses to DS-7300a, and ferroptosis induction represents a promising therapeutic approach to overcome resistance to DS-7300a in malignancies harboring TP53 defects. |  |  |  |  |  |  | |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  |  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n| |  |  |  |  |  |  |  | |\n|  | Oncogene (2026) 45:3753–3764; [https://doi.org/10.1038/s41388-026-03921-7](https://doi.org/10.1038/s41388-026-03921-7) |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |  |\n\nINTRODUCTION  \nThe tumor suppressor TP53 plays a central role in regulating cell division, cell death, and the response to DNA damage [1–3] . Genetic mutations or deletions in TP53 are found in more than half of cancers [4–8] and are associated with higher rates of metastasis and poorer clinical outcomes. Prostate cancer (PCa) is the most diagnosed cancer and the second leading cause of cancer death in men in the United States [9] . While most patients initially respond to androgen deprivation therapy, their disease often progresses to castration-resistant prostate cancer (CRPC) [10, 11] . Genetic alterations (mutations and deletions) in the TP53 gene are observed in about 30% of primary PCa cases [12] and are further enriched in metastatic disease and CRPC [5] . Together with PTENand RB1, TP53 defects have been used to characterize a clinicalbiological subset of androgen-indifferent prostate tumors, termed aggressive variant prostate cancers (AVPC) [8] . Treatm","cbCaiudhhpxf1p3f","https://ap.wps.com/l/cbCaiudhhpxf1p3f","pdf",3823716,12,"English","# Introduction\n## TP53-driven resistance and unmet therapeutic needs\n## ADC mechanism and TOP1 inhibitor payload (DXd)\n## Study rationale for ferroptosis-based sensitization","[{\"question\":\"What is DS-7300a and what payload does it deliver?\",\"answer\":\"DS-7300a is a B7-H3-targeting antibody-drug conjugate. It is armed with DXd, a selective topoisomerase I inhibitor payload.\"},{\"question\":\"How does TP53 status affect the response to DS-7300a?\",\"answer\":\"Functional p53 is required for DS-7300a efficacy. TP53 defects confer resistance by impairing sensing of DXd-induced DNA damage, leading to low apoptosis and senescence despite DNA damage-related signaling being engaged in p53-proficient cells.\"},{\"question\":\"How was ferroptosis used to overcome DS-7300a resistance?\",\"answer\":\"DS-7300a treatment increases lipid peroxidation in TP53-deficient cancer cells and upregulates GPX4. Pharmacological inhibition of GPX4 induces ferroptosis and enhances DS-7300a efficacy in TP53-deficient tumor models.\"}]","Enhancing the efficacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deficient tumors by inducing ferroptosis | PDF",1790090944,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fca4277ab6b1343a54ccea4b0768f76.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa9992c0699d96529d1a7c0926635729.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54f7ace15adf81f662b7e5397aef47e9.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79e66fcb46448e606a5a04dfbd25741f.webp",980,1301]